NCT04061980 2025-11-19Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid CancerProvidence Health & ServicesPhase 2 Active not recruiting24 enrolled
NCT03246958 2025-06-19Nivolumab Plus Ipilimumab in Thyroid CancerDana-Farber Cancer InstitutePhase 2 Completed53 enrolled 19 charts
NCT06638931 2025-05-28ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Active not recruiting28 enrolled